ArticlemedRxiv : the preprint server for health sciences2024
Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.
Timothy S Johnston, Shuk Hang Li, Mark M Painter, Reilly K Atkinson, Naomi R Douek, David B Reeg, Daniel C Douek, E John Wherry, Scott E Hensley
Open access · greenAbstract readPreprint
In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 8 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors at 4 institutions in 3 countries.
Timothy S JohnstonDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Shuk Hang LiDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Mark M PainterInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Reilly K AtkinsonDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Naomi R DouekInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
David B ReegInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Daniel C DouekVaccine Research Center, NIAID, NIH; Bethesda, MD.
E John WherryInstitute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.
Scott E HensleyDepartment of Microbiology, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA.ORCID 0000-0002-2928-7506 Parker Institute for Cancer Immunotherapy · USNational Institutes of Health · USUniversity of Pennsylvania · USUniversity of Freiburg · DE
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8MModeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2MTemporal control of differentiation and epigenetics of Exhausted CD8 T cells by ToxR01AI155577 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2020 to 2024
$2.7MCellular and transcriptional control of exhausted CD8 T cells lineage dynamicsR01AI105343 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2014 to 2017
$1.6MNIAID NIH HHS 75N93021C00015NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI105343NIAID NIH HHS R01 AI155577NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI149680
6 · The paper itselfAbstract
The spike glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to accumulate substitutions, leading to breakthrough infections of vaccinated individuals and prompting the development of updated booster vaccines. Here, we determined the specificity and functionality of antibody and B cell responses following exposure to BA.5 and XBB variants in individuals who received ancestral SARS-CoV-2 mRNA vaccines. BA.5 exposures elicited antibody responses that primarily targeted epitopes conserved between the BA.5 and ancestral spike, with poor reactivity to the XBB.1.5 variant. XBB exposures also elicited antibody responses that targeted epitopes conserved between the XBB.1.5 and ancestral spike. However, unlike BA.5, a single XBB exposure elicited low levels of XBB.1.5-specific antibodies and B cells in some individuals. Pre-existing cross-reactive B cells and antibodies were correlated with stronger overall responses to XBB but weaker XBB-specific responses, suggesting that baseline immunity influences the activation of variant-specific SARS-CoV-2 responses.
Indexed as
antibodiesB cellsimmune evasionimmune imprintingmRNA vaccinesOmicron BA.5original antigenic sinSARS-CoV-2viral evolutionXBB.1.5
Identifiers
PMID38260304
PMCPMC10802657
OpenAlexW4390700603
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390